CytomX Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by CytomX Therapeutics, Inc. on October 24, 2017, reporting events that occurred on October 23, 2017. The company is a Delaware corporation headquartered in South San Francisco, California, and is classified as an emerging growth company.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on corporate governance changes.
Material Changes
The primary material event reported is the appointment of a new director to the Board of Directors:
- Appointment: Charles S. Fuchs, MD, MPH, was appointed as a Class III director effective October 23, 2017, filling a vacancy.
- Term: His initial term expires at the Company's 2018 annual meeting of stockholders.
- Compensation: Dr. Fuchs receives standard non-employee director compensation.
- Equity Grant: Upon appointment, he received an option to purchase 28,000 shares of common stock under the 2015 Equity Incentive Plan.
- Option Details: The exercise price is $20.04 per share (the closing price on October 23, 2017). The option vests monthly over 36 months (1/36th per month), contingent on continued service.
- Indemnification: The Company entered into a standard indemnification agreement with Dr. Fuchs.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding business outlook, financial guidance, or specific risks. It notes that there are no arrangements or understandings between Dr. Fuchs and the Company regarding his appointment, and no transactions exceeding $120,000 involving Dr. Fuchs have occurred since the beginning of the last fiscal year.
Key Facts for Investor Verification
- Verify the vesting schedule and exercise price of the 28,000 share option granted to Dr. Fuchs.
- Review the "Director Compensation" section in the Company's Form 10-K/A filed on March 20, 2017, for details on standard non-employee director pay.
- Confirm the status of the Class III director vacancy that Dr. Fuchs is filling.
- Check the press release filed as Exhibit 99.1 for additional context on the appointment.